Pichia pastoris, grown in fermentor culture, and purified. The final pure product is of high specific ATPase activity and is soluble at low detergent concentration. 120 g of cells yielded 6 mg of pure Pgp; >4 kg of cells were obtained from a single fermentor run. Properties of the pure protein were similar to those of previous preparations, except there was significant ATPase activity in absence of added lipid. Mutant mouse MDR3 Pglycoproteins were purified by the same procedure after growth of cells in flask culture, with similar yields and purity. This procedure should open up new avenues of structural, biophysical, and biochemical studies of Pgp. Equilibrium nucleotide-binding parameters of wildtype mouse MDR3 Pgp were studied using 2-(3)-O-(2,4,6-trinitrophenyl)adenosine tri-and diphosphate. Both analogs were found to bind with K d in the low micromolar range, to a single class of site, with no evidence of cooperativity. ATP displacement of the analogs was seen. Similar binding was seen with K429R/K1072R and D551N/D1196N mutant mouse MDR3 Pgp, showing that these Walker A and B mutations had no significant effect on affinity or stoichiometry of nucleotide binding. These residues, known to be critical for catalysis, are concluded to be involved primarily in stabilization of the catalytic transition state in Pgp.
P-glycoprotein (Pgp)
1 is a plasma membrane-located, ATPdriven drug efflux pump that confers multidrug resistance on mammalian cells (1) (2) (3) (4) (5) . It occurs commonly in human tumors and is a major obstacle to successful chemotherapy. Consisting of two duplicated "halves" and a total length of around 1280 residues, it is a prominent member of the ABC transporter superfamily (6) and shows the typical ABC transporter domain arrangement consisting of two transmembrane domains (TMD) and two nucleotide-binding sites (NBS), in a linear sequence that can be represented as TMD1-NBS1-TMD2-NBS2. Current studies in many laboratories are aimed at understanding Pgp structure, function, normal physiology, and pharmacology.
Our laboratory has studied the two nucleotide sites, and we have established that both are catalytic MgATP hydrolysis sites, which interact together closely (7) (8) (9) (10) . Earlier, we proposed (11) a catalytic mechanism for Pgp, in which the two NBS hydrolyze MgATP alternately, and hydrolysis is coupled to drug transport from an inner-facing, higher affinity, drug-binding site to an outer-facing, lower affinity site. Subsequent reports (12) (13) (14) (15) (16) have supported and extended this proposed mechanism. Further work (17) (18) (19) (20) on the structure and location of the drug-binding sites has shown that certain transmembrane ␣-helices are involved in forming these sites, and work (21) with the closely related LmrA protein showed that transport is indeed from the inner lipid leaflet to the outer surface as proposed in Ref. 22 . The mechanism of coupling of energy of ATP hydrolysis to transport of drugs is not well understood, however, at the present time. A preliminary structure of Pgp at low resolution has been published (23) , and, clearly, future structure resolution will be pivotal to more complete understanding of function.
Studies of structure and function of proteins depend on availability of pure material. Many of the advances made in the Pgp field so far have come from utilization of the multidrug-resistant Chinese hamster ovary cell model, originally devised by Ling and colleagues (24) . By using enriched plasma membranes or purified Pgp (23, (25) (26) (27) from such cells, an extensive body of literature has been built up, dealing with enzymatic, transport, and structural properties of Pgp and using a range of biochemical and biophysical approaches. The Chinese hamster ovary cell model has two drawbacks, however, which are that it is too expensive to scale up to truly large scale production of pure Pgp, and mutant proteins cannot be purified.
Mutagenesis has been successfully employed in studies of Pgp in membrane preparations from insect (Sf9) or cultured mammalian cells and has proved extremely valuable, for example see Refs. 13 and 28 -30. However, there is no method so far for purifying mutant Pgp in significant amounts. Earlier methods (31) produced only 10-g amounts of protein, and more recent methods, although improved (12) , have not yet provided large quantities (Ͼ200 g). Among promising methods for further scale-up, expression of Pgp in yeast cells appears foremost. At time of writing, Pgp has been purified from Saccharomyces cerevisiae (32) and Pichia pastoris (12, 33) , with the latter system shown to be amenable to expression and purification of mutant Pgp (12) .
In this paper we have scaled up purification of Pgp using growth of P. pastoris cells in a fermentor and a new purification method. The final material is pure, active in detergent-soluble form, and activated to high specific ATPase activity on addition of minimal amounts of lipid. Wild-type mouse MDR3 Pgp and several mutant mouse MDR3 proteins containing substitutions in the Walker A and Walker B consensus sequences were purified by the same procedure. The purified Pgp is readily amenable to fluorescence analysis. We report the nucleotidebinding properties of wild-type and mutant Pgp using the fluorescent nucleotides TNP-ATP and TNP-ADP, and we demonstrate that mutations in the Walker A and B sequences that fully impair catalysis have little or no effect on equilibrium nucleotide binding.
EXPERIMENTAL PROCEDURES
Materials-n-Dodecyl-␤-D-maltoside with low intrinsic fluorescence was from Anatrace (catalog number D310). Imidazole with low intrinsic fluorescence was from Sigma (catalog number I-0250). Ni 2ϩ -NTA agarose resin was from Qiagen. C219 monoclonal antibody was from Signet Laboratories. Escherichia coli lipids were from Avanti (acetone/etherprecipitated, catalog number 100600). Asolectin (crude soybean phospholipid) was from Sigma. TNP-ATP and TNP-ADP (sodium salts) were obtained from Molecular Probes. Antifoaming agent MAZU DF204 (catalog number 558958) was from BASF Corp. All other chemicals were from recognized sources.
Strains of P. pastoris Expressing Wild-type Mouse MDR3 Pgp and Mutant Mouse MDR3
Pgp-A strain carrying wild-type mouse MDR3 cDNA incorporated into the chromosome behind the AOX1 promoter was described previously (12, 33) . Strains carrying the following mutations were described (12): K429R, K1072R, and K429R/K1072R (Walker A single and double mutants); D551N, D1196N, and D551N/D1196N (Walker B single and double mutants). In all cases, the Pgp contained a C-terminal six His-tag to facilitate purification.
Media for Growth of P. pastoris Cells-The P. pastoris cell line GS115 (Invitrogen, license number 145 457) was used and grown according to the supplier's guidelines. Media were as follows: MGY, 1.34% w/v yeast nitrogen base without amino acid (Difco), 1% v/v glycerol, 0.4 mg/liter biotin; MM, same as MGY but with 0.5% v/v methanol replacing glycerol.
Growth of P. pastoris Cells in 2-Liter Flasks-Conditions for growth of P. pastoris GS115 cells transformed with wild-type or mutant mouse MDR3 Pgp were as described previously (33, 34) . Briefly, a single colony from an MGY agar plate was inoculated into 10 ml of liquid MGY medium and incubated at 30°C with shaking to A 600 of 2.0 (ϳ18 h), then this 10 ml was inoculated into 1 liter of MGY medium in a 2-liter baffled Fernbach flask. Incubation at 30°C with shaking to A 600 of 2.0 was continued (ϳ24 h), then the cells were centrifuged in sterile bottles (2500 ϫ g for 10 min at 23°C). The cells were resuspended to A 600 of 2.0 in 0.5% v/v methanol-containing MM medium, and 1 liter was added to a 2-liter baffled Fernbach flask covered with cheesecloth. Incubation continued for 72 h with additions of methanol (0.5% v/v) at 24 and 48 h. Cells were finally collected by centrifugation at 2500 ϫ g for 10 min at 23°C and resuspended in ice-cold "homogenization buffer" (0.33 M sucrose, 300 mM Tris-Cl, pH 7.4, 1 mM EDTA, 1 mM EGTA, 2 mM DTT, 100 mM 6-aminohexanoic acid) at a concentration of 0.5 g wet wt cells/ml buffer.
Growth of P. pastoris Cells in the Fermentor-The fermentation was done according to Invitrogen guidelines in a BiofloIV bench-top fermenter (New Brunswick Scientific) equipped with a 20-liter waterjacketed stainless steel vessel and microprocessor control of pH, dissolved oxygen, agitation, temperature, and nutrient-feed and with electronic foam control. The temperature was kept at 29°C. The vessel containing medium composed of 0.93 g/liter CaSO 4 , 18.2 g/liter K 2 SO 4 , 14.9 g/liter MgSO 4 ⅐7H 2 O, and 4% v/v glycerol in 10-liter volume was sterilized for 30 min at 122°C, then 9 g/liter (NH 4 ) 2 SO 4 , 25 g/liter sodium hexametaphosphate, and 4.25 ml/liter trace salts (Invitrogen, PTM 1 ) were added aseptically. Fermentation proceeded in three phases. To begin the initial "glycerol batch phase," 1-liter of start-up culture was added. The start-up culture consisted of 1 liter of cells grown in flasks in MGY, as described above. Agitation was maintained at a minimum of 500 rpm and was programmed to increase up to 1000 rpm to maintain a dissolved oxygen above 40% of the initial setting (100%). A pH of 5.0 was maintained using 14% (w/v) ammonium hydroxide. The glycerol batch phase was run until glycerol was completely consumed (24 h), i.e. when A 600 was stable for 2 h. A yield of 104 g wet wt cells/liter was achieved at this stage. The second phase was the "glycerol-fed phase," that was initiated by continuously feeding the culture with a medium containing 50% (v/v) glycerol and 12 ml/liter PTM 1 trace salts. The feed rate was 18.15 ml/h/liter and was carried out until cell density was 213 g wet wt cells/liter (4 -5 h). The feed was stopped for 2 h to ensure total glycerol depletion. The third phase was the "methanol-fed phase." The methanol feed, containing 12 ml of PTM 1 trace salts per liter of methanol, was initiated at the rate of 1 ml/h/liter of initial fermentation volume for 13 h, was increased to 2 ml/h/liter for 24 h, then further to 2.4 ml/h/liter for 24 h, and finally to 3 ml/h/liter for the rest of the methanol-fed phase. This phase lasted in total for 6 days. A sample of cells was taken daily and checked for A 600 , cell density (wet wt cells/liter), and Pgp expression. The cells reached a cell density of 425 g/liter on day 6. The fermenter was cooled to 10°C prior to harvesting. The cells were centrifuged at 2500 ϫ g for 10 min at 4°C, washed twice with distilled water, and frozen at Ϫ70°C in 15% (v/v) glycerol in water.
"Rapid Membrane Preparation" for Monitoring Expression of Pgp After Methanol Induction of Cells-A rapid procedure was used to obtain a crude membrane fraction from cells grown in the fermentor or flasks, to monitor Pgp expression. Cells from 10 ml of flask culture or 0.5-1 ml of fermentor culture were centrifuged at 2000 ϫ g for 5 min and resuspended in 0.5 ml of homogenization buffer (above). The suspension was transferred to a 2-ml microcentrifuge tube and centrifuged at 2000 ϫ g for 5 min. The pellet was resuspended in 300 l of homogenization buffer containing 10 g/ml leupeptin and pepstatin A, 2.5 g/ml chymostatin, and 1 mM PMSF, and then 100 l of acid-washed glass beads (Sigma G-9268, 425-600 m) were added. The mixture was vortexed vigorously six times for 1 min each, with 2 min on ice between each vortexing. The supernatant was spun at 2000 ϫ g for 2 min to remove beads, then at 14,000 ϫ g for 20 min, and then finally the remaining supernatant was spun at 250,000 ϫ g for 60 min. The pellet ("rapid membranes," 100 -200 g of protein) was dissolved in 2% (w/v) SDS, analyzed by protein assay, SDS-gel electophoresis, and Western blotting with C219 antibody against Pgp.
Preparation of "Microsomes" from Cells-For flask cultures, frozen cells in homogenization buffer were rapidly thawed at 30°C. For fermentor cultures, cells were thawed, centrifuged at 2500 ϫ g for 10 min, and then resuspended in ice-cold homogenization buffer at a concentration of 0.5 g wet wt cells per ml. All further steps were at 4°C or on ice. Protease inhibitors were added as follows: 2 g/ml pepstatin A and leupeptin, 0.5 g/ml chymostatin, 1 mM PMSF. Cells were passed one to three times through a French press set at 20,000 pounds/square inch, adding fresh PMSF (1 mM) every 25 min and adjusting the pH to 7.4 after each pass with 1 M Tris-Cl, pH 7.4. The homogenate was centrifuged at 3,500 ϫ g for 15 min, and the pellet was discarded, and the supernatant was centrifuged at 14,000 ϫ g for 30 min. These steps removed unbroken cells, nuclei, and mitochondrial fractions, which contained little Pgp as shown by Western blotting. The supernatant was centrifuged at 200,000 ϫ g for 90 min, and the pellet containing the microsomes was resuspended in buffer (50 mM Tris-Cl, pH 7.4, 10% v/v glycerol containing 2 g/ml pepstatin A and leupeptin, 0.5 g/ml chymostatin, 1 mM PMSF), to the same volume as before the 200,000 ϫ g centrifugation. Resuspension was achieved initially by use of a paintbrush and then by passage through a 22-gauge needle, followed by 10 strokes by hand in a Potter-Elvehjem Teflon pestle homogenizer. The microsomes were recentrifuged at 200,000 ϫ g for 60 min and resuspended as above, this time in "buffer A" consisting of 50 mM Tris-Cl, pH 8.0, 50 mM NaCl, 30% v/v glycerol, 1 mM 2-mercaptoethanol, 10 mM imidazole, plus protease inhibitors as follows: 2 g/ml pepstatin A and leupeptin, 0.5 g/ml chymostatin, 1 mM PMSF. At this stage the microsomes could be stored frozen at Ϫ70°C. Yield of microsomes was 40 -50 mg per 10 g wet wt cells.
Solubilization of Pgp by Detergent-To 1 volume of thawed microsomes (4 mg protein/ml) was added an equal volume of 1.2% w/v n-dodecyl-␤-D-maltoside (DM) in buffer A plus protease inhibitors as above. The suspension was mixed by inversion and allowed to sit on ice for 10 min. It was then centrifuged at 60,000 ϫ g for 30 min. and applied to a column of Whatman DE52 cellulose, which had been precycled according to the manufacturer's instructions and equilibrated in buffer B. The column volume was 2 ml of resin per 100 mg of solubilized microsomal protein. Pgp did not adsorb and was collected in the flow-through. The column was washed with 2 column volumes of buffer B, and the wash fraction was pooled with the flow-through. This material contained pure Pgp. Elution of the DE52 column with 300 mM NaCl in buffer B showed that all the contaminant proteins in the eluate from the Ni 2ϩ -NTA column step were adsorbed to the DE52 column. Pgp was concentrated by ultrafiltration under N 2 using an Amicon concentrator with a YM10 or XM50 membrane membrane to a final concentration of 1-2 mg/ml. The concentrated material was aliquoted and stored at Ϫ70°C.
Activation of Purified Pgp by Lipid and DTT-Lipid stocks were made from asolectin or E. coli lipids by adding 40 mM Tris-Cl, pH 7.4, 0.1 mM EGTA, to solid lipid and sonicating in a bath sonicator at 4°C until the suspension clarified (final concentration was 20 mg of lipid/ ml). This stock was stored under N 2 . For activation, Pgp and lipid were mixed at the appropriate ratio (w/w) in 40 mM Tris-Cl, pH 7.4, 0.1 mM EGTA, with DTT (2 mM), and incubated 20 min at 23°C, then sonicated in a bath sonicator at 4°C for 30 s. The protein was stored on ice for the minimum period until assay.
Fluorescence Measurements-Fluorescence measurements were made in a SPEX Fluorolog 2 fluorimeter. For TNP-nucleotide binding experiments, using stirred 2-ml cuvettes at room temperature, excitation wavelength was 408 nm, and emission spectra from 500 to 600 nm were collected. Pgp was activated as above using 2/1 ratio of asolectin/ Pgp (w/w) before addition to the cuvette. Final Pgp concentration in the cuvette was 140 nM. Control cuvettes containing every component except Pgp (including lipid and detergent) were used to correct for inner filter and volume effects. The buffer was 50 mM Tris-SO 4 , pH 7.5, with 2 mM MgCl 2 ("with Mg 2ϩ ") or with 0.5 mM EDTA ("without Mg 2ϩ "). TNP-nucleotides were added, and the fluorescence spectra were taken when equilibration was reached (Յ3 min). Concentrations of stock solutions of TNP-nucleotides were determined by measurement of absorption at 408 nm using an extinction coefficient of 26,400 M Ϫ1 cm Ϫ1 (35) . Titration curves were fit using nonlinear regression to a model assuming a single class of sites, which in all cases gave a satisfactory fit to the data. Further details of individual experiments are given in figure legends. Routine Procedures-SDS-gel electrophoresis on 8 or 10% gels used the Bio-Rad Minigel system with manufacturer supplied gels. Western blotting followed standard procedures and used the monoclonal antiPgp C219 antibody (Signet Laboratories). ATPase assay at 37°C by continuous linked-enzyme procedure was as in Ref. 7 . Protein estimation was by the BCA (36) or Bradford (37) methods.
RESULTS

Large Scale Purification of Wild-type Mouse MDR3 Pgp Using Fermentor-grown Cells
The procedure is described in detail under "Experimental Procedures." A strain of P. pastoris expressing wild-type mouse MDR3 protein (12, 33) was grown in the fermentor. After initiation of the methanol feed to induce Pgp expression, small samples were taken at daily intervals for analysis of Pgp. Cells were broken, and a rapid membrane preparation was made as described under "Experimental Procedures." SDS-gel electrophoresis and Western blotting were performed. Pgp expression was evident first at 24 h after beginning the methanol feed, and the Pgp level remained constant as a fraction of total membrane protein each 24 h for 6 days (data not shown). However, cell density increased steadily from 234 g/liter at day 1 to 425 g/liter at day 6, thus yielding a total of over 4 kg of cells at harvesting on day 6 after methanol induction.
Previously Gros and colleagues (12) purified Pgp from the same P. pastoris strain, from cells grown in flask culture, using a procedure involving preparation of purified plasma membranes by sucrose gradient centrifugation, solubilization of Pgp from purified plasma membranes, Ni 2ϩ -NTA (His-tag) chromatography, and reconstitution into proteoliposomes. Here we adapted this procedure as follows. First, we avoided purifying plasma membranes, because we were dealing with large amounts of cells, and also we wished to harvest any Pgp resident in intracellular membrane locations. Thus we prepared a microsome fraction and solubilized Pgp from it directly. Second, we changed the solubilization conditions, omitting addition of exogenous lipid. Third, we added a DEAE-cellulose chromatography step, which removed all contaminants in material obtained at the Ni 2ϩ -NTA step. Fourth, we omitted reconstitution in proteoliposomes, so that the final product would be detergent-soluble and monodisperse for fluorescence studies. Table I (columns 2 and 3) shows a typical purification of wild-type mouse MDR3 Pgp from a 120-g batch of fermentorgrown cells, which yielded 5.8 mg of final product. The procedure has been repeated many times with excellent reproducibility. Yield of pure Pgp ranged from 1% of microsomal protein (as in Table I ) up to 1.5% and was usually close to 0.05 mg of Pgp per g wet wt cells. Fig. 1 shows a Coomassie Blue-stained SDS gel documenting the purification procedure, with the final pure Pgp shown in lane 7. We have run larger amounts of pure Pgp (up to 10 g) on the gel and have seen no contaminants. The very minor band just visible at around 60 kDa on the gel is a proteolysis product from Pgp, as demonstrated by Western blotting with C219 antibody and also vanadate trapping with 8-azido-[␣-
32 P]ATP. At the stage of detergent solubilization, the average distribution of total protein was around 80% in the supernatant and 20% in the pellet. Western blotting showed that the supernatant was enriched in Pgp so that extraction of Pgp was efficient. Recovery of Pgp at the Ni 2ϩ -NTA and DE52 chromatography steps is excellent. The band in the 300 mM NaCl eluate from the DE52 column which runs at the same a Purification of mutant K429R/K1072R is described. Other mutants as listed in Fig. 2 legend showed the same behavior. ATPase activity was very low to zero in all the mutants.
b ATPase was assayed in presence of 150 M verapamil and after activation with DTT and lipid (E. coli lipid or asolectin at 2/1 w/w ratio).
position as Pgp (Fig. 1, lane 8 ) was shown to be Pgp by Western blotting. Thus a small amount of Pgp adsorbs to the DE52 column, but the bulk clearly did not adsorb under our conditions. The final pure Pgp after concentration to 1-2 mg/ml is in a buffer containing 0.1% DM and behaves as a soluble protein.
It is stable to freezing at Ϫ70°C; however, loss of activity was noted on multiple freezing and thawing.
ATPase Activity of Purified Wild-type Mouse MDR3 Pgp
Typically the pure Pgp was divided into aliquots and stored at Ϫ70°C. Data described are for material frozen and thawed once. Preincubation with DTT was necessary to achieve maximal activity, commonly an enhancement of 5-to 8-fold was seen, and this step was performed routinely. Preincubation with 2 mM DTT for 20 min at room temperature was usually sufficient for maximal activation, but higher concentrations of DTT (8 mM) were also used.
Activity in Absence of Added Lipid-The protein as prepared, without addition of any lipid, did have ATPase activity. Typical specific ATPase activity was 0.17 mol/min/mg Pgp at 10 mM MgATP, pH 7.5, 37°C, in absence of verapamil, with a range of 0.09 to 0.3 in five different preparations. In presence of 150 M verapamil the specific ATPase activity was 1.5 (range seen was 0.7 to 2.6). This variation could be due to different intrinsic lipid content. On average verapamil gave 9-fold enhancement. The effect of detergent DM on ATPase activity in absence of added lipid (Ϯverapamil) was studied, and it was found that activity was highest at DM concentrations between 0.0004 and 0.01% (w/w) in the assay and that activity declined above 0.01% DM. Thus in fluorescence assays, if lipid was not added, DM concentration was kept below 0.01%. K m (MgATP) for ATPase activity in absence of added lipid (with 150 M verapamil and at 0.008% DM concentration) was measured with MgATP concentration varied from 0.05 to 8 mM and was 0.38 mM.
Activity in Presence of Added Lipid-Addition of lipid increased activity considerably (Fig. 2) . The procedure used for activation by lipid consisted of incubation of Pgp with lipid at room temperature in the presence of DTT, followed by sonication, as described under "Experimental Procedures." We tested asolectin and E. coli lipids, which were found to be of equivalent efficacy in increasing activity. As can be seen from Fig. 2 , maximal activity was reached at low ratio of added lipid/Pgp ratio, around 1/1 (w/w), and we used 2/1 ratio for fluorescence experiments and ATPase assays. At these low ratios of added lipid, the Pgp retained the optical properties of a non-particulate, soluble protein. Specific ATPase activity in the presence of verapamil (150 M) was high at 4.9 mol/min/mg (range was 4.5 to 5.2 in five different preparations). There was strong enhancement of activity by verapamil (10-fold), and the verapamil concentration required for 50% activation was 6 M, similar to that encountered in other preparations. Above 200 M, verapamil began to inhibit, consistent with previous work. K m (MgATP) in the presence of 150 M verapamil, where maximal activation was reached, was 0.36 mM, similar to many previous estimations of K m . Measurement of ATPase activity of lipid-activated Pgp in the presence of 150 M verapamil at varying pH values revealed a broad pH optimum at around 7.8 -8.0, in confirmation of previous work on mouse MDR3 Pgp (33) . We confirmed that the Pgp could be reconstituted into proteoliposomes following a previous procedure (12, 33) and that the same maximal activity was seen in reconstituted Pgp as seen in Fig. 2 . Lipid-activated Pgp was strongly inhibited by sodium orthovanadate and by beryllium fluoride as seen in previous preparations (9, 38) . Vanadate-and beryllium fluoride-trapping experiments were performed with 8-azido-[␣-32 P]ATP as described (7) (8) (9) and demonstrated that labeling of the Pgp occurred. Recovery of ATPase activity after vanadate or beryllium fluoride trapping of MgADP occurred with similar time courses to those previously reported.
Tryptophan Fluorescence and Content of Pure Wild-type Pgp
Tryptophan fluorescence was readily evident when pure Pgp was added at 140 nM concentration (asolectin/Pgp ratio ϭ 2/1 (w/w)) to a fluorescence cuvette containing 50 mM Tris-SO 4 , pH 7.5. Excitation was at 295 nm, and uncorrected maximum of the broad emission spectrum was at 338 nm (not shown). Addition of MgATP or MgADP (1 mM) caused no change in fluorescence emission spectrum, showing that the 11 intrinsic wildtype Trp residues are not responsive to nucleotide. We attempted to assay effects of transport substrates or modulators on Trp fluorescence. Unfortunately, many well known Pgp transport substrates, including verapamil, vinblastine, colchicine, and numerous others, could not be used because they absorbed strongly in the same spectral region as Trp. However valinomycin, known to be a strong stimulator of Pgp ATPase activity (12, 33) , was not subject to this limitation. Valinomycin at saturating concentration (40 -100 M) gave a small enhancement of total Trp fluorescence of wild-type Pgp (12-15% at the wavelength maximum, with no change in max ). Attempts to measure K d values were, however, unsatisfactory due to the small signal. In future studies, this work will be extended by utilizing a wider range of drugs and by use of specifically engineered Pgp, in which the wild-type Trp residues are replaced, and specific Trp residues are substituted, to enlarge the fluorescence signal and to locate the part(s) of the Pgp molecule where the signal is originating.
To estimate Trp content, pure Pgp was dissolved in 6 M guanidine HCl (188 nM Pgp in 250 l volume), and the fluorescence signal at 350 nm was measured. Comparison of this signal with that of purified F 1 -ATPase (which contains 9 Trp per mol and was used as standard) gave a Trp content of purified Pgp of 10.6 mol/mol (range ϭ 10.2-11.3 in four experiments). Mouse MDR3 Pgp contains 11 Trp/mol, so this provides an independent criterion of purity.
Purification of Mutant Pgp
The mutant Pgp species studied contained either Lys to Arg mutations in the Walker A sequence(s) or Asp to Asn mutations in the Walker B sequence(s) and were as follows: in the Walker A motif K429R, K1072R, and K429R/K1072R; and in the Walker B motif D551N, D1196N, and D551N/D1196N . Mutant strains were grown in a 2-liter flask culture, which typically yielded 40 g of cells, the same as for wild type. A typical purification yield for one mutant is shown in Table I . All the mutants behaved similarly in the purification scheme and gave similar yields (1.0 -2.0 mg of pure Pgp). An SDS gel of purified mutant Pgp proteins (Fig. 3) demonstrated that mutant Pgp was quite pure. Specific ATPase activity of all the mutant proteins in the presence or absence of verapamil and after activation by lipid and DTT was very low or zero, in agreement with previous work (12) .
TNP-ATP and TNP-ADP Binding Measurements with Wild-type Mouse MDR3 Pgp
Previous reports showed that TNP-ATP was hydrolyzed slowly by Pgp (26) and that both TNP-ATP and TNP-ADP were inhibitors of ATP hydrolysis (26, 39) . Initial experiments here showed that on addition of TNP-ATP at micromolar concentration to 140 nM Pgp, enhancement of the fluorescence signal of TNP-ATP occurred, by a factor of 3 or more depending on conditions, and was accompanied by a shift of fluorescence emission spectrum such that the maximum was now at 535 nm as opposed to 550 nm in the absence of Pgp. Such a spectral shift has been seen before with intact, purified Pgp (26) or with the isolated recombinant N-and C-terminal nucleotide binding domains of Pgp (40, 41) and is known to be indicative of TNPnucleotide binding to nucleotide-binding sites of proteins (35) . We used the fluorescence signal at 530 nm to estimate binding of TNP-ATP to Pgp. In all cases the signal of a control cuvette containing every component except the Pgp was subtracted, as described under "Experimental Procedures." Fig. 4A shows the results of a typical experiment in which wild-type Pgp was first activated with 2 mM DTT and lipid and then titrated with TNP-ATP in the absence of Mg 2ϩ . Saturation was reached, and the calculated K d value was 2.7 M (mean of several experiments). The same experiment in the presence of 2 mM MgCl 2 gave a K d of 5.9 M (data not shown). Maximal fluorescence enhancement was 3-fold in the absence of Mg 2ϩ and 4.5-fold in its presence. Similar curves were generated when Pgp was activated by DTT in the absence of lipid (data not shown). Whether lipid was present or absent, the final DM concentration was 0.0087%, and the samples were translucent. All subsequent experiments were done in the presence of lipid. Control experiments showed that verapamil (150 M) gave no interference with these fluorescence measurements. Fig. 4 , B and C, shows binding of TNP-ATP in the presence of verapamil and in the absence or presence of Mg 2ϩ , respectively. K d values obtained were 3.2 and 6.3 M in the absence and presence of Mg 2ϩ . In both cases, the presence of verapamil caused additional significant enhancement of fluorescence (by 2-3-fold, compare y axes in Fig. 4, A-C) .
NaATP was found to cause displacement of bound TNP-ATP. Fig. 5 shows reduction in the fluorescence signal at 530 nm (expressed as "⌬ fluorescence") when NaATP was added in increasing concentrations to a sample of Pgp to which TNP-ATP was already bound. Concomitantly the maximal emission of the sample shifted to 550 nm, indicating displacement of TNP-ATP. Typically around 70 -90% extrapolated maximal displacement of TNP-nucleotide occurred. Calculation of K d (ATP) from the displacement curves gave a value of approximately 10 mM. Similar results were found in the presence or absence of verapamil and/or 2 mM MgCl 2 . When Na 2 SO 4 (100 mM) was substituted for NaATP, no change in fluorescence signal occurred, indicating that increase in ionic strength was not responsible for TNP-ATP displacement.
Summarizing, these results demonstrate equilibrium binding of TNP-ATP to Pgp nucleotide sites, in the presence and absence of added lipids, with K d values in the low micromolar 
Binding of TNP-ATP and TNP-ADP to Walker A and Walker B Mutant Pgp
Initial experiments were performed on K429R/K1072R and D551N/1196N double mutants. TNP-ATP binding occurred to the K429R/K1072R mutant with K d of 2.1 M and fluorescence enhancement of 3-fold in the absence of Mg 2ϩ (Fig. 6A) . Thus K d was slightly lower than in wild type, but the fluorescence enhancement was similar. The presence or absence of verapamil had the same effects on fluorescence enhancement as seen in wild type and did not significantly affect K d . TNP-ADP binding occurred to the K429R/K1072R mutant with a K d of 2.8 M (absence of Mg 2ϩ and in the presence or absence of verapamil), which was slightly lower than in wild type, and the fluorescence enhancements were similar to wild type.
With the D551N/D1196N mutant, TNP-ATP was also bound (see Fig. 6B ). In absence of Mg 2ϩ , K d was 1.9 M, which again is slightly lower than in wild type, with the fluorescence enhancement being similar to that seen in wild type. As in wild type, verapamil increased the fluorescence enhancement at saturation without significant effect on K d , and Mg 2ϩ increased K d to 4.4 M, with a concomitant increase in fluorescence enhancement at saturation as in wild type. TNP-ADP binding occurred to the D551N/D1196N mutant, with a K d of 2.5 M (absence of Mg 2ϩ and the presence or absence of verapamil), which was slightly lower than in wild type, and the fluorescence enhancement was similar to wild type.
ATP displacement of bound TNP-ATP was seen in both mutants (Fig. 7) and was in the range of 76 -92% when extrapolated to the maximal value, with a calculated apparent K d (ATP) of 7 to 18 mM in different experiments.
Summarizing, these data showed that these mutants behaved very similarly to wild type. In both mutants, binding affinities for TNP-ATP and TNP-ADP were slightly higher than in wild type. The fluorescence enhancements at saturation, and the displacement of TNP-nucleotide by ATP, gave no indication of any significant reduction in binding stoichiometry in the two mutants, when compared with the wild type. The presence of Mg 2ϩ had the same effects in both mutants as in wild type, i.e. a doubling of K d value and increased fluorescence. Verapamil had the same effects in both mutants as in wild type. Since the mutants studied contained the amino acid substitution in both nucleotide binding domains, we did not consider it necessary to go on to study the "single" Walker A and Walker B mutant proteins. 
DISCUSSION
Large Scale Purification of P-glycoprotein-We describe a new purification of P-glycoprotein that yields pure protein of high specific ATPase activity. Expression of Pgp is in the yeast P. pastoris. The method is shown to be applicable to wild-type and mutant mouse MDR3 proteins. 2 A fermentor culture yields Ͼ4 kg of cells, which will potentially yield 200 mg of pure Pgp. As prepared the pure Pgp is soluble in 0.1% DM and remained soluble at much lower concentrations of detergent. We characterized the ATPase activity in detail and confirmed that in most aspects the new preparation had properties the same as those of previous preparations. Briefly, activity had pH optimum around 7.8 -8.0, was strongly stimulated by verapamil, was inhibited by vanadate and beryllium fluoride in a manner involving trapping of nucleotide, had K m (MgATP) close to millimolar, and was activated by addition of lipid. A novel feature of the preparation was that it showed significant, verapamilstimulated ATPase activity even without addition of lipid and that just small amounts of added lipid yielded maximum activity. This work has important implications for the next generation of biochemical, biophysical, and structural studies on Ppg, because it overcomes limitations imposed previously by our inability to obtain large amounts of pure wild-type or mutant protein. Extensive crystallography, electron microscopy, fluorescence, and many other kinds of experiments will now be feasible.
Fluorescence Assays of Pgp Nucleotide-binding Sites-Initially we investigated intrinsic Trp fluorescence as a possible probe of nucleotide binding, and we found that whereas high quality Trp emission spectra were obtained with wild-type Pgp, addition of ATP or ADP did not change the spectra, thus no information on nucleotide binding could be obtained. However, the data do establish the potential feasibility of inserting Trp probes as a valuable investigative technique.
We then studied binding of the fluorescent nucleotide analogs TNP-ATP and TNP-ADP, introduced by Hiratsuka and Uchida (35) , and since that time used widely in studies of ATPand ADP-binding sites in proteins. Previously, these nucleotide analogs have been used to study binding to the isolated N-and C-terminal NBS of wild-type Pgp (40, 41) and to purified intact wild-type Pgp from Chinese hamster ovary cells (26) . We found that both of the nucleotide analogs bound to wild-type pure Pgp with K d values in the low micromolar range. Binding affinity was similar in the presence or absence of verapamil or added lipid and was 2-fold lower in the presence than in the absence of Mg 2ϩ . In all cases the binding curves were satisfactorily fit by a single It was not possible from our data to calculate binding stoichiometry of the nucleotide analogs. As noted below, data in Ref. 26 demonstrated binding of TNP-ATP at saturation to both of the nucleotide sites of purified, chemically modified hamster Pgp. Previous data utilizing 8-azido-ATP labeling has indicated that both NBS are capable of binding nucleotide (12, 13, 29) . Protection of both of the two NBS by ATP from NEM labeling or NBD-Cl labeling has also been noted, showing that ATP binds to both NBS (10, 28, 43) . In addition both NBS have been shown to be catalytic sites (8) . If TNP-ATP and TNP-ADP are indeed binding to both nucleotide sites at saturation in our experiments, then our finding of a single K d at saturation under equilibrium binding conditions would indicate that both NBS bind each nucleotide with the same affinity. More work will be required to establish definitively this point.
ATP caused displacement of bound TNP-ATP and TNP-ADP, confirming that binding was to the NBS. (26) studied TNP-ATP and TNP-ADP binding to purified, intact wild-type hamster Pgp and found a single class of binding site for each. Their data suggested that both nucleotide sites were occupied by TNP-ATP and TNP-ADP, since in Pgp that had been chemically modified by 2-(4Ј-maleimidylanilino)naphthalenesulfonic acid, which reacts with the Cys in the Walker A sequence of both NBS (44) , the fluorescence of the probe was fully quenched by the TNP-nucleotides (26) . However, their calculated K d values of 43 and 36 M, for TNP-ATP and TNP-ADP, respectively, are much higher than the values reported in this work. The major difference between the two preparations is that Liu and Sharom (26) utilized a two-step extraction with CHAPS as the purification procedure; nevertheless, the K m (MgATP) was similar to that found here, so that an explanation for difference in binding affinity for the TNP-nucleotides is not evident.
As was noted above, in our experiments the fluorescence signal of bound TNP-nucleotide was enhanced to varying degrees, depending on the experimental conditions. For example, the presence of Mg 2ϩ gave additional enhancement as compared with its absence, and verapamil consistently gave the highest enhancement. These effects likely represent changes in the environment around the nucleotide bound in the catalytic sites, probably to a more hydrophobic milieu. Thus the fluorescence of bound TNP-ATP responds significantly to binding of verapamil in the drug-binding sites.
This paper is the first to study binding of TNP-ATP and TNP-ADP to mutant Pgp, and the results obtained with the mutant proteins K429R/K1072R and D551N/D1196N are of interest in relation to the role of the Walker A and Walker B conserved Lys and Asp residues. In both of these mutants, ATPase activity is strongly impaired (Refs. 12, 13, 31, and this work), yet we found that binding of TNP-ATP and TNP-ADP was remarkably similar to that of the wild type, as reflected by both K d values and fluorescence enhancements. This was a surprising finding. In other proteins, mutation of these residues commonly impairs both hydrolysis and binding of substrate or substrate analogs. Both of the residues lie close to the phosphate moiety of the bound nucleotide in the x-ray structures of the NBS of the ABC transporters HisP (47) and RbsA 3 2 In work to be reported elsewhere we found that the method was also applicable to purification of human Cys-less Pgp.
3 C. S. Stauffacher, personal communication.
and might have been expected to affect nucleotide binding parameters on this basis. However it should be noted that, in previous studies on Pgp, labeling by 8-azido-ATP was not affected by these mutations (12, 13, 29) . Our conclusion is that, whereas these residues play key roles in accelerating catalysis, provision of binding energy by interaction with the nucleotide substrate is not a major factor in this acceleration. Rather their major role is likely to occur at the step of stabilization of the catalytic transition state, consistent with results in Ref. 12 .
DTT Activation of Pgp-The mouse MDR3 wild-type Pgp was consistently seen to be activated 5-8-fold by DTT, and this was routinely done before assays. This Pgp contains nine total Cys residues, of which three are in NBS2 and one is in NBS1. The Walker A sequence in each of NBS1 and NBS2 contains one Cys, which has shown to be the target of the reagents NEM (28) and NBD-Cl (43), both of which inactivate ATPase activity. Cys-less Pgp is insensitive to both of these reagents (28, 43) , and we have found that the ATPase activity of purified Cys-less protein was not affected by preincubation with DTT (data not shown). In vacuolar ATPase there is also a Cys in the Walker A sequence of the catalytic subunit, at the same position as in Pgp, and the vacuolar ATPase is inhibited by N-ethylmaleimide and NBD-Cl (45) . Furthermore, there is evidence that formation of a disulfide bond between the Walker A Cys and another Cys close to the catalytic site inhibits activity and is a physiological mechanism of regulation of ATPase activity in vacuolar ATPase (45, 46) . It is therefore intriguing to consider that a somewhat similar mechanism might operate in Pgp, with a disulfide forming between a Walker A Cys and one of the other Cys in NBD2. This suggestion warrants further study, and it could lead to new ways to inhibit Pgp activity in tumors.
